Surmodics (SRDX) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Surmodics (NASDAQ: SRDX) in the last few weeks:

• 11/23/2024 – Surmodics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/15/2024 – Surmodics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/7/2024 – Surmodics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 11/7/2024 – Surmodics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/30/2024 – Surmodics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/22/2024 – Surmodics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/14/2024 – Surmodics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/6/2024 – Surmodics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/28/2024 – Surmodics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Surmodics Stock Performance

Surmodics stock opened at $39.58 on Wednesday. The stock has a fifty day moving average price of $38.50 and a 200 day moving average price of $39.53. The company has a current ratio of 3.96, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25. Surmodics, Inc. has a 52 week low of $25.17 and a 52 week high of $42.44. The firm has a market capitalization of $567.18 million, a P/E ratio of -48.86 and a beta of 1.20.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.14. The company had revenue of $33.23 million for the quarter, compared to analyst estimates of $30.69 million. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.79%. Equities research analysts anticipate that Surmodics, Inc. will post 0.17 earnings per share for the current year.

Hedge Funds Weigh In On Surmodics

A number of hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. acquired a new stake in shares of Surmodics in the third quarter valued at about $1,190,000. Renaissance Technologies LLC boosted its holdings in Surmodics by 5.0% in the 2nd quarter. Renaissance Technologies LLC now owns 606,538 shares of the company’s stock worth $25,499,000 after acquiring an additional 28,990 shares during the period. Gardner Lewis Asset Management L P acquired a new stake in Surmodics in the second quarter valued at approximately $8,531,000. Sagefield Capital LP purchased a new stake in shares of Surmodics during the second quarter valued at approximately $2,350,000. Finally, Trium Capital LLP acquired a new position in shares of Surmodics during the second quarter worth $1,406,000. Hedge funds and other institutional investors own 96.63% of the company’s stock.

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).